Value (Business Strategy and Financial Management)

ePoster Presentations

EP-153 - Cost Savings Associated with Teleretinal Imaging in Primary Care

Monday, April 30
4:25 PM - 4:40 PM
Location: Education Zone, Booth 2416, Screen 5

The high costs of diabetes in the United States are well known, with estimated total costs at approximately $245 billion, including $176 billion in direct medical costs each year(1). Much of this cost is attributed to comorbid conditions like kidney disease, heart disease, and eye disease. As an example, diabetic retinopathy (DR), the leading cause of blindness in working-age adults in the United States(2), accounts for $2 billion in health care costs, as well as additional indirect costs related to lost productivity. Welch Allyn and RTI Health Solutions have developed an economic model to demonstrate the effect of teleretinal screening on rates of blindness and costs of treatment.

The American Diabetes Association, along with several other professional organizations, recommends that all diabetic patients in the U.S. have an annual dilated retinal exam (DRE) to evaluate for the presence or absence of DR(3). Currently, on average, less than 65% of patients are compliant with these recommendations(4). Due to late detection of disease, many of these patients will require costly treatment and many will suffer preventable severe vision loss from DR.

As a method to increase DRE compliance and early detection of sight-threatening DR, teleretinal imaging uses specialized cameras to acquire retinal photos in primary care clinics. Ophthalmologists remotely interpret the retinal images and return a diagnostic report to the primary care provider. Patients with vision-threatening eye disease are urged to follow up with an ophthalmologist for a dilated eye exam.

The effectiveness of teleretinal imaging is well documented, with evaluation rates increasing from 30% to over 90%(5). However, this study is the first comprehensive assessment of current costs of DR and the monetary effect of the implementation of teleretinal screening.

Welch Allyn and RTI Health Solutions have developed an economic model that employs the gold-standard for cost-effectiveness models - a Markov-based approach with health states to capture: (1) the incidence and progression of DR, including progression to clinically significant macular edema (CSME) and irreversible severe vision loss; (2) the detection and treatment of vision-threatening DR and CSME; and (3) death over a 10-year time period for both the entire U.S. diabetic population as well as only the Medicare population.

Early results of the model show that with the current paradigm of DR detection, that is, referral to an ophthalmologist for a DRE by the primary care provider, the rate of blindness from DR will continue to increase over the next 10 years. Additionally, costs associated with screening and treatment will rise steadily, largely because DR is not being detected in the early stages when it can be treated effectively and cost effectively. Implementing teleretinal screening nationwide could reverse the trend and decrease the rate of severe vision loss from diabetes. In addition to preserving vision, teleretinal imaging results in a global cost savings, largely due to less-costly screening and the cost-effectiveness of early treatment. Additional statistics, including actual costs saved and percent reduction in diabetes-related blindness, will be included in the final presentation.

Learning Objectives:

Kristen L. Stebbins

Sr. Clinical Researcher
Welch Allyn

Kristen Stebbins joined Welch Allyn in April 2014 as a Clinical Researcher. She is responsible for management and oversight of clinical projects for Vision Care products, including diabetic retinopathy and vision screening devices. She designs, executes, and oversees studies for product development, regulatory submissions, and market adoption. Prior to her role as a clinical researcher, Kristen worked as a registered nurse and a radar engineer. Kristen has a BS in Electrical Engineering from Johns Hopkins University, a BS in Nursing from SUNY Binghamton University, and a Masters of Science in Public Health from Excelsior College.

Presentation(s):

Send Email for Kristen Stebbins

Seema Garg

Associate Professor of Ophthalmology
University of North Carolina

Seema Garg, MD, PhD, is a medical retina specialist and is currently an Associate Professor of Ophthalmology at the University of North Carolina. She completed her doctorate in the area of biomedical engineering and medical imaging. She then went on to medical school and ophthalmology residency at Duke University. She completed her medical retina fellowship at Northwestern University. In addition taking care of patients with a variety of retinal conditions, she has been passionate about building a telemedicine network for diabetic retinopathy evaluation in NC since 2009 to prevent the leading cause of preventable blindness. Her work was funded by the Duke Endowment to develop this program in sites across the state of North Carolina.

Presentation(s):

Send Email for Seema Garg


Assets

EP-153 - Cost Savings Associated with Teleretinal Imaging in Primary Care



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Cost Savings Associated with Teleretinal Imaging in Primary Care